Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLR1A | O95602 | 2/20 | 0.44 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3084923 | 0.81 | PARP1 (1.00) | PARP1AURKBMAPTCACNA1GKDM4E | |
| SCHEMBL3083967 | 0.80 | PARP1 (0.64) | PARP1AURKBTP53MAPTKMT2A | |
| SCHEMBL3077205 | 0.80 | PARP1 (0.75) | PARP1AURKBMAPTKMT2AKDM4E | |
| SCHEMBL3080392 | 0.79 | PARP1 (0.62) | PARP1AURKBTP53 | |
| SCHEMBL3074505 | 0.79 | PARP1 (0.83) | PARP1AURKBMAPTKDM4EALDH1A1 | |
| SCHEMBL3074379 | 0.79 | PARP1 (0.87) | PARP1AURKBMAPTCACNA1GKMT2A | |
| SCHEMBL3344406 | 0.79 | PARP1 (0.83) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3074794 | 0.78 | PARP1 (0.69) | PARP1AURKBTP53MAPTRXFP1 | |
| SCHEMBL3084927 | 0.77 | PARP1 (1.00) | PARP1AURKBTP53RXFP1ALDH1A1 | |
| SCHEMBL30902531 | 0.77 | PARP1 (0.67) | PARP1AURKBTP53MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114948-B1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-11-25 | — | — | US | disclosed |
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135571-A1 | NOVEL PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-7790721-B2 | Pyrroloquinoxalinone inhibitors of poly(ADP-ribose)polymerase | ABBOTT LABORATORIES (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2114948-A2 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | Abbott Laboratories (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008082887-A2 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161292-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161292-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | PARP1 1/4885AURKB 1768/4885TP53 177/4885 |
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | PIM2, PIM1, PIM3 | PARP1 1573/4885AURKB 269/4885TP53 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.